Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
Last trade$1.45
Day change-$0.11 (-7.05%)
Day range$1.45 – $1.56
Volume59,025
Market cap$554M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for EVO.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for EVO.
Recent news
Company coverage with links to the original publishers.
BIO-Europe 2026 will host over 6,000 senior leaders from the global biopharma industry in Cologne, Germany, from November 9-11, 2026. The 32nd annual edition expands beyond partnering to become Europe's largest biopharma strategy forum, featuring seven integrated tracks covering regulatory, clinical, and manufacturing strategy, with focus on partnerships, innovation, and addressing industry challenges.
The global drug repurposing market is projected to grow from USD 34.79 billion in 2025 to USD 50.91 billion by 2035 at a CAGR of 3.93%. North America leads with 39% market share, while Asia-Pacific shows the fastest growth at 5.02% CAGR. Small molecules dominate at 67% market share, with oncology and neurology as primary therapeutic areas. AI and machine learning are accelerating drug discovery, though intellectual property rights remain a key barrier.
BCC Research's mid-year assessment highlights AI-driven discovery, precision oncology, and connected health as major growth themes in the life sciences sector. Key opportunities include smart inhalers with AI integration, genomic profiling platforms, cardiovascular drug innovations, and in vitro toxicity testing. The sector benefits from aging populations, regulatory support for non-animal testing, and emerging market expansion, though risks include patent expirations and reimbursement variability.
Gilead Sciences announced a $3.15 billion acquisition of Tubulis GmbH to strengthen its oncology pipeline, adding the promising antibody-drug conjugate TUB-040 for ovarian cancer treatment. The deal includes up to $1.85 billion in contingent milestone payments. This acquisition follows Gilead's March purchase of Ouro Medicines for $1.675 billion, highlighting the company's broader pipeline expansion strategy.
Johnson Fistel, PLLP is investigating whether Evotec SE complied with federal securities laws following the company's announcement of its 'Horizon' restructuring initiative on March 10, 2026. The investigation focuses on potential investor losses related to Evotec's financial guidance projecting €700-780 million in revenue and €0-40 million in adjusted EBITDA for fiscal year 2026, along with €100 million in restructuring charges expected over 2026-2028.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Jan 11, 2019
$0.0722
Jan 22, 2019
recurring
Dec 12, 2018
$0.0451
Dec 20, 2018
recurring
Nov 8, 2018
$0.0451
Nov 19, 2018
recurring
Oct 10, 2018
$0.0451
Oct 18, 2018
recurring
Sep 13, 2018
$0.0451
Sep 21, 2018
recurring
Stock splits
Historical share-structure events and their execution dates.